|
SoluLinK, Inc., who produce biomolecular conjugation products and services for life science, diagnostic and nanotechnology markets, announced today the appointment of David McCarty to its Board of Directors.
Mr McCarty is currently the President and CEO of PanCel. He has held senior positions in the health care industry for over 30 years. Most recently, Mr McCarty was President and CEO of NOVEX, which he successfully merged with Invitrogen (a publicly-traded research products company) in August 1999. He served on the Board of Directors of Invitrogen from August 1999 to August 2004. Prior to joining NOVEX in 1997, Mr McCarty was the President and CEO of Alexon Biomedical, a medical diagnostics company, which he led to a successful financial turnaround and a profitable strategic sale to Sybron International (now Apogent Technologies) in early 1997. His other professional experience includes senior operating positions at Gen-Probe, Allergenetics, Calbiochem-Behring, Boehringer Mannheim Diagnostics and Hyland Diagnostics. Mr McCarty received his BS in chemistry from California State University at Northridge and his MBA from California State University at Long Beach.
“It is an honour to have David McCarty join SoluLinK’s board. He is a proven leader and brings market savvy and practical business expertise to SoluLinK from his successful experience managing and directing multiple bioscience companies,” stated Steve DeGraw President and Chief Business Officer of SoluLinK. “His knowledge of all aspects of the management of rapidly growing life science companies will be invaluable to SoluLink’s continued growth.”
About SoluLinK
SoluLinK is a privately held company located in San Diego, California, USA. SoluLinK develops, manufactures and markets products and services for the conjugation of proteins, oligonucleotides, peptides and antibodies to one another, and to solid surfaces for array, research assay, diagnostic and therapeutics applications. SoluLinK’s biotinylation reagent ChromaLink® is an example of such products that that create, improve and enable the performance of arrays, research assays, diagnostics and certain types of therapeutics. SoluLinK markets these products directly and through distributors and licensing partners world-wide.
|
All News